Application of Oral Bacteriotherapy to Promote Anal HPV Clearance in HIV Positive Individuals

HIV Clinical Trial

— HPVinHIV  

Official title:

HPVinHIV: Study of Anal HPV Infection in the Setting of HIV Infected Individuals

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04099433
• Other study ID #: 4590
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2019
• Est. completion date: September 1, 2020

Study information

• Verified date: September 2019
• Source: University of Roma La Sapienza
• Contact: Gabriella d'Ettorre, Professor, MD
• Phone: 0649970801
• Email: gabriella.dettorre[@]uniroma1.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Published studies suggest that oral probiotic intake can promote the clearance of HPV genital infection and HPV related genital dysplasia in HIV negative women. In the present randomized, double blind, placebo controlled study, investigators will evaluate the ability of oral bacterio-therapy to enhance the clearance of anal HPV infection and anal HPV related dysplasia in HIV infected subjects.

Participants will be evaluated for anal HPV infection and anal dysplasia before and after a 6 months course of daily investigational product intake (Viviomixx® or placebo). HPV infection rate and presence of dysplasia at baseline and at the end of the study will be compared.

Description:

Squamous Cell Carcinoma (SCC) of the anus and the anal canal represents a major concern for the HIV infected population, with incidence rates in the different sub populations (women, men, MSM) that are grater than those observed for other common neoplasms in the same HIV negative sub-populations. Nowadays, screening for anal precancerous dysplasia has been included in most national and international HIV management guidelines; in particular, italian guidelines suggest to screen for the presence of HPV related dysplasia:

• HIV+ MSM

• All individuals with previous or current evidence of ant-genital condyloma

• Women with cytology abnormalities on cervical Pap-smear Since no direct anti-HPV drug is currently available and control or clearance of the infection is possible only trough the effect of immune response, interest is addressed to find strategies to promote spontaneous clearance of infection.

In published studies, oral bacterio-therapy demonstrated the ability to promote HPV clearance and HPV related dysplasia regression in HIV negative women.

In the present randomized, double blind, placebo controlled trial, 40 HIV infected individuals with HPV related anal dysplasia will be enrolled.

At baseline participants will undergo:

• anal HPV research and identification

• anal cytology

• anal brushing for evaluation of local inflammatory milieu and microbiota

Subjects with identified HPV anal infection and anal dysplasia will undergo High Resolution Anoscopy (HRA).

During HRA, extra biopsies of identified abnormal areas and biopsies of normal mucosa will be obtained. Extra biopsies will be used to investigate the distribution of intra-epithelial immune cells populations.

Participants will then undergo 6 months of oral supplementation with probiotics (Vivomixx®) or placebo.

At the end of the supplementation period (Vivomixx or placebo), participants will undergo:

• anal HPV research and identification

• anal cytology

• anal brushing for evaluation of local inflammatory milieu and microbiota

• HRA

During HRA, extra biopsies of identified abnormal areas and biopsies of normal mucosa will be obtained. Extra biopsies will be used to investigate the distribution of intra-epithelial immune cells populations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: September 1, 2020
• Est. primary completion date: March 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV infected individuals >18 years old

• stable and effective antiretroviral therapy since at least 12 months

• HPV associated anal dysplasia

• patient willing to provide written informed consent

Exclusion Criteria:

• impossibility to intake the investigational product

• any contraindication to blood sampling

• inflammatory bowel disease

• use of antibiotics during the 3 months prior to the enrollment in the study

• pregnancy

Related Conditions & MeSH terms

• Anal Dysplasia
• HIV

Intervention

Dietary Supplement:
• Vivomixx
Individuals in the interventional arm will undergo daily oral intake of probiotic supplement

Other:
• Placebo
Individuals in the placebo arm will undergo daily oral intake of placebo supplement

Locations

Country	Name	City	State
Italy	Department of Pubblic Health and Infectious Diseases, "Sapienza" University of Rome	Rome	RM

Sponsors (1)

Lead Sponsor	Collaborator
University of Roma La Sapienza

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in the number of HPV positive anal swabs	Clearance of anal HPV infection will be defined as: negative swab at the end of the study in participants with positive swab at baseline; positive swab at the end of the study that shows a different genotype from baseline	Anal swabs for HPV detection and genotyping will be performed at baseline and after the 6 months duration of the intervention
Primary	Change from baseline in the number of dysplastic lesions	Clearance of anal dysplasia will be defined as: - normal histology in biopsies repeated at the end of the study on areas that showed the presence of histologically defined dysplasia at baseline.	Areas of the anal canal that were biopsied at baseline and whom histology showed the presence of dysplasia will undergo a second biopsy after the 6 months duration of the intervention
Secondary	Rate of adverse events	The rate of adverse events occurred during the study period will be evaluated and compared between both groups	This measure will be assessed after the 6 months duration of the intervention
Secondary	Comparison between intra-epithelial NK lymphocytes subpopulation in normal mucosa and dysplastic mucosa	Biopsies from dysplastic lesions and from normal mucosa will be taken at baseline. Biopsies will also be taken at the end of the study from previously biopsied areas, from normal mucosa and eventually from dysplastic areas that were not present at baseline. Intra-epithelial lymphocytes will be extracted from the biopsy tissue and stained to differentiate and quantify CD56+NK lymphocytes by flowcytometry. Changes from baseline will be expressed as relative difference.	Biopsies and intra-epithelial lymphocytes extraction will be performed at baseline and after the 6 months duration of the intervention
Secondary	Comparison between intra-epithelial CD4+ T lymphocytes subpopulation in normal mucosa and dysplastic mucosa	Biopsies from dysplastic lesions and from normal mucosa will be taken at baseline. Biopsies will also be taken at the end of the study from previously biopsied areas, from normal mucosa and eventually from dysplastic areas that were not present at baseline. Intra-epithelial lymphocytes will be extracted from the biopsy tissue and stained to differentiate and quantify CD4+ T lymphocytes by flowcytometry. Changes from baseline will be expressed as relative difference.	Biopsies and intra-epithelial lymphocytes extraction will be performed at baseline and after the 6 months duration of the intervention
Secondary	Comparison between intra-epithelial CD8+ T lymphocytes subpopulation in normal mucosa and dysplastic mucosa	Biopsies from dysplastic lesions and from normal mucosa will be taken at baseline. Biopsies will also be taken at the end of the study from previously biopsied areas, from normal mucosa and eventually from dysplastic areas that were not present at baseline. Intra-epithelial lymphocytes will be extracted from the biopsy tissue and stained to differentiate and quantify CD8+ T lymphocytes by flowcytometry. Changes from baseline will be expressed as relative difference.	Biopsies and intra-epithelial lymphocytes extraction will be performed at baseline and after the 6 months duration of the intervention